Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
24.96
-1.34 (-5.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Earnings Preview For Mirum Pharmaceuticals
March 08, 2022
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement....
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs
February 26, 2022
Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to...
Via
Talk Markets
Expert Ratings For Mirum Pharmaceuticals
September 30, 2021
Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst rat...
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
January 11, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
January 04, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
December 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
December 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
December 06, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 22, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
November 17, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For November 15, 2021
November 15, 2021
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...
Via
Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
November 08, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Thursday
September 30, 2021
Jefferies raised Perrigo Company plc (NYSE:PRGO) pr...
Via
Benzinga
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
September 29, 2021
The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 29, 2021
Gainers Regencell Bioscience (NASDAQ:RGC)...
Via
Benzinga
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
September 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
September 21, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals
September 20, 2021
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ...
Via
Benzinga
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
September 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.